Group 1: China Ping An - The core strategy of China Ping An is "comprehensive finance + medical care and elderly care," which aims to create a new value growth pole through a "product + service" model, leading to long-term stable profit growth [3][4] - The report suggests that the current market valuation of China Ping An is low, with a PEV of 0.75, and recommends a target market value of 1.6 trillion yuan, corresponding to a target price of 88.53 yuan per share [3][4] - The aging population in China and the increasing importance of commercial health insurance in medical payments are expected to enhance the effectiveness of the "product + service" model, positioning it as a new growth driver for the company [3][4] Group 2: Steel Research High Temperature Alloy - Steel Research High Temperature Alloy is a leading company in the high-temperature alloy sector, benefiting from strong demand in the aerospace industry and the trend towards technological self-sufficiency [5][6] - The company is expected to achieve steady growth in net profit, with forecasts of 132 million yuan, 152 million yuan, and 172 million yuan for 2025 to 2027, respectively [5][6] - The report highlights the resilience of the high-temperature alloy industry, driven by increasing defense budgets and the upgrade of aerospace equipment, which supports long-term demand [6][7] Group 3: CSPC Pharmaceutical Group - CSPC Pharmaceutical Group is recognized for its strong innovation capabilities, with a focus on oncology and chronic disease treatment pipelines, and has established an international business development ecosystem [8][9] - The company has entered a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs, which is expected to generate significant revenue potential [9][10] - The report predicts EPS growth of 48%, 36%, and -7% for 2025 to 2027, with a target price of 16.58 HKD per share [8][9] Group 4: Real Estate Market - The real estate market in China is currently in a deep adjustment phase, with only 19% of cities showing signs of bottoming out as of Q4 2025 [18][19] - New home prices are experiencing significant fluctuations, particularly in first-tier cities, while second-hand home prices are generally declining [19][20] - The report indicates that the inventory clearance cycle is extending, with first-tier cities reaching 19-28 months and some second-tier cities exceeding 38 months [20] Group 5: Robotics and Automation - The company is actively expanding into the humanoid robotics sector, with new product launches expected to drive growth [21][22] - The report forecasts EPS of 1.14, 1.47, and 1.83 yuan for 2025 to 2027, with a target price of 147.00 yuan per share [21][22] - The company is leveraging its expertise in micro-drive systems to enhance its competitive position in the robotics market [22][23] Group 6: Energy Storage Sector - The energy storage sector is anticipated to see significant growth, with the introduction of capacity pricing mechanisms in provinces like Qinghai [36][37] - The report suggests that the demand for energy storage systems and batteries will increase, recommending several key stocks in this sector [36][37] - The expected growth rate for energy storage demand in 2026 is projected to be around 50% [38]

25 年业绩高增长，医药新能源业务发力 联化科技(002250) 联化科技首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 刘威(分析师) | 0755-82764281 | liuwei7@gtht.com | S0880525040100 | | 李智(分析师) | 021-23185842 | lizhi3@gtht.com | S0880525040045 | 本报告导读： 公司医药业务稳步增长，研发能力进一步增强，新能源业务及海外马来西亚基地成 为新的增长点。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 6,442 | 5,677 | 6,408 | 7,559 | 8,826 | | (+/-)% | -18.1% | -11.9% | 12.9% | 18.0% | 16.8% | | 净利润(归母 ...

25 年业绩高增长，医药新能源业务发力 联化科技(002250) 联化科技首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 刘威(分析师) | 0755-82764281 | liuwei7@gtht.com | S0880525040100 | | 李智(分析师) | 021-23185842 | lizhi3@gtht.com | S0880525040045 | 本报告导读： 公司医药业务稳步增长，研发能力进一步增强，新能源业务及海外马来西亚基地成 为新的增长点。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 6,442 | 5,677 | 6,408 | 7,559 | 8,826 | | (+/-)% | -18.1% | -11.9% | 12.9% | 18.0% | 16.8% | | 净利润(归母 ...

（文章来源：证券日报） 证券日报网讯 2月25日，联化科技在互动平台回答投资者提问时表示，公司医药业务致力于为客户提供 端到端一体化服务，持续努力提高业务水平跟随客户发展。 ...

Company and Industry Summary Company Overview - The company focuses on agricultural protection and pharmaceuticals, covering four main sectors: agricultural protection, pharmaceuticals, functional chemicals, and equipment and engineering technology [1][1] - Established nearly 40 years ago, the company has 8 chemical production bases, 3 mechanical equipment production bases, and 3 R&D centers in China, along with one production base each in the UK and Malaysia [1][1] Key Points Agricultural Protection Sector - The agricultural protection CDMO (Contract Development and Manufacturing Organization) business has emerged from a low point and is now in a stable growth phase, serving major global agricultural protection companies [1][1] - Revenue in this sector is expected to slightly decline in 2023-2024 due to downstream inventory destocking [1][1] Pharmaceutical Sector - The company’s pharmaceutical CDMO business has seen a continuous increase in revenue share over the years, primarily serving the top twenty global pharmaceutical companies [2][2] - The pharmaceutical business is extending into the small nucleic acid drug raw material field, with rapid revenue growth anticipated due to increasing downstream customer demand [3][3] New Energy Sector - The company entered the new energy sector in 2021, with LiFSI (Lithium bis(fluorosulfonyl)imide) already commercialized [3][3] - The completion of technical upgrades for lithium hexafluorophosphate will enable the production of 200,000 tons of electrolyte, with 100,000 tons already constructed, contributing to new revenue streams [3][3] Financial Projections - Projected revenues for 2025-2027 are estimated at 6.312 billion, 7.373 billion, and 8.813 billion yuan, respectively, with net profits of 393 million, 513 million, and 617 million yuan [4][4] - Corresponding price-to-earnings ratios (PE) are expected to be 28.0, 21.5, and 17.8 times, respectively, with an initial coverage rating of "Accumulate" [4][4] Additional Insights - The company is replacing some old production capacity with new capacity for patented products, which is expected to enhance gross margins as the supply of off-patent products clears [2][2] - Strengthening relationships with partners is anticipated to lead to rapid growth in demand for patented products [2][2]

Core Insights - Longhua Technology (联化科技) is positioned as a leading player in the agricultural and pharmaceutical CDMO sectors, with significant achievements in small nucleic acid CDMO and potential in functional chemicals [1][2] Business Overview - Longhua Technology has established a collaborative development framework across four core industrial segments: agricultural protection, pharmaceuticals, functional chemicals, and equipment & engineering services [2] - The agricultural protection segment generated revenue of 1.702 billion yuan in the first half of 2025, with a gross margin increase of 9.48% year-on-year [2] - The pharmaceutical segment, focusing on APIs and intermediates, achieved revenue of 1.018 billion yuan in the first half of 2025, reflecting a year-on-year growth of 42.80% [2] Small Nucleic Acid CDMO - The company is leveraging small nucleic acid CDMO to tap into new growth opportunities, with advantages over traditional small molecule and antibody drugs, including broader target selection and higher success rates [3] - Since 2022, the market for small nucleic acid drugs has seen significant activity, with 32 transactions totaling 29.022 billion USD in 2025, indicating strong commercial value [3] - Longhua Technology has developed scalable production processes for modified nucleotides and has established a high-efficiency delivery system for nucleic acid drugs, enhancing its competitive edge [3] Functional Chemicals and Market Potential - The functional chemicals segment reported revenue of 0.265 billion yuan in the first half of 2025, marking a year-on-year doubling [4] - The company is focusing on lithium battery materials, including lithium hexafluorophosphate and LiFSI, with ongoing product development in various testing phases [4] - The National Development and Reform Commission's new storage action plan aims for over 1.8 million kilowatts by 2027, which is expected to drive significant market demand in the energy storage sector [4] Financial Performance - For the first three quarters of 2025, Longhua Technology reported total revenue of 4.718 billion yuan, an increase of 8.25% year-on-year, and a net profit of 316 million yuan, surging by 871.65% [1] - The projected net profit for 2025 is estimated to be between 350 million and 420 million yuan, representing a year-on-year growth of 239.35% to 307.22% [4]

Summary of Key Points Core Viewpoint - The company has approved a guarantee limit of 70 million yuan for its subsidiaries, with specific limits based on their asset-liability ratios, and has signed a mortgage contract with a bank to secure debts for its wholly-owned subsidiary [1][2]. Group 1: Guarantee Overview - The company held board and shareholder meetings to approve a guarantee limit of 70 million yuan for its subsidiaries, with 50 million yuan for subsidiaries with an asset-liability ratio below 70% and 20 million yuan for those above [1]. - The company has a total guarantee amount of up to 580 million yuan, which represents 89.59% of its latest audited net assets [6]. Group 2: Guarantee Progress - A mortgage contract was signed with China Agricultural Bank for the subsidiary, covering debts with a maximum guarantee amount of 46.64 million yuan and 98.16 million yuan [3]. - The guarantee covers various financial services including loans, bank guarantees, and other credit-related services [3]. Group 3: Guarantee Agreement Details - The mortgage is secured by real estate, and the company must register the mortgage within five days of the contract's effectiveness [4]. - The contract becomes effective upon signing or stamping by all parties involved [4]. Group 4: Guarantee Status - As of the announcement date, the company's guarantee balance is 119.85 million yuan, accounting for 18.51% of its latest audited net assets, with no overdue guarantees or litigation issues reported [6].

Group 1 - The core point of the article is that Lianhua Technology (002250) announced that neither the company nor its controlling subsidiaries have experienced overdue guarantees, litigation-related guarantees, or losses due to being judged against in guarantees [1] Group 2 - The announcement reflects the company's stable financial position and risk management practices [1] - The absence of litigation and guarantee-related losses indicates a lower risk profile for investors [1] - This information may enhance investor confidence in Lianhua Technology's operational integrity [1]

证券代码：002250 证券简称：联化科技 公告编号：2026-003 联化科技股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保情况概述 联化科技股份有限公司（以下简称"公司"、"联化科技"）分别于2025年10 月9日召开了第九届董事会第二次会议和2025年10月28日召开了2025年第二次临 时股东会，审议通过了《关于公司为子公司提供担保额度预计的议案》，同意为 公司为子公司新增担保额度70,000万元，其中为最近一期资产负债率低于70%的 控股子公司新增担保额度不超过50,000万元，为最近一期资产负债率高于70%的 控股子公司新增担保额度不超过等值人民币20,000万元。关于担保额度的情况， 具体详见公司刊登于《证券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn） 的《关于公司为子公司提供担保额度预计的公告》（公告编号：2025-047）。 二、担保进展情况 公司与中国农业银行股份有限公司台州黄岩支行于2026年2月5日签署了编 号为33100620260005611和 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Insights - The company is positioned as a leading provider of chemical technology solutions, focusing on agricultural CDMO, pharmaceutical small molecules, and small nucleic acid CDMO, with significant achievements in functional chemicals [3][5]. - The agricultural sector is experiencing steady growth, while the pharmaceutical CDMO sector shows promising prospects, particularly in small nucleic acids, which are gaining traction in the market [6][7]. - The company is expanding its footprint in the new energy sector, particularly in lithium battery materials, which presents substantial growth potential [8]. Summary by Relevant Sections Company Overview - Founded in 1985 and located in Taizhou, Zhejiang Province, the company has evolved from producing flavor and fragrance intermediates to becoming a global custom manufacturing service provider in agriculture, pharmaceuticals, and functional chemicals [5][19]. - The company has established a comprehensive business platform that meets diverse customer needs across various stages of product development and lifecycle [21][24]. Agricultural Sector - The global agricultural industry is entering a mature phase, with projected sales of $77.2 billion in 2024, reflecting a 6.8% year-over-year decline. However, the sector is expected to expand steadily due to ongoing population growth [6][53]. - The competitive landscape is characterized by oligopolistic structures, with the top five companies holding a 57.4% market share in 2024, driven by innovation and strong brand channels [6][53]. Pharmaceutical CDMO - The company has been involved in small molecule CDMO for over a decade, with a robust revenue growth trajectory since 2017. A significant rebound is expected in 2025, with projected revenue of 1.018 billion yuan, a 42.8% increase year-over-year [7]. - The company is expanding into the small nucleic acid drug market, which is projected to see 32 transactions worth $29.022 billion in 2025, highlighting the growing commercial value of this segment [7]. Functional Chemicals - The lithium-ion battery electrolyte market is rapidly growing, with expected shipments reaching 2.235 million tons by 2025, a 46.4% increase. The company is focusing on lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide as key products in this sector [8][24]. - The company is well-positioned to capitalize on the increasing demand for lithium battery materials, with a focus on developing high-performance products [8]. Financial Performance - The company is expected to achieve net profits of 410 million, 630 million, and 790 million yuan for the years 2025 to 2027, respectively, indicating strong financial growth prospects [9].